A novel protective effect of erythropoietin in the infarcted heart.

Erythropoietin (EPO) has been shown to protect neurons from ischemic stroke, but can also increase thrombotic events and mortality rates in patients with ischemic heart disease. We reasoned that benefits of EPO might be offset by increases in hematocrit and evaluated the direct effects of EPO in the ischemic heart. We show that preconditioning with EPO protects H9c2 myoblasts in vitro and cardiomyocytes in vivo against ischemic injury. EPO treatment leads to significantly improved cardiac function following myocardial infarction. This protection is associated with mitigation of myocyte apoptosis, translating into more viable myocardium and less ventricular dysfunction. EPO-mediated myocyte survival appears to involve Akt activation. Importantly, cardioprotective effects of EPO were seen without an increase in hematocrit (eliminating oxygen delivery as an etiologic factor in myocyte survival and function), demonstrating that EPO can directly protect the ischemic and infarcted heart.

[1]  K. Ozawa,et al.  Activation of extracellular signal‐regulated kinases ERK1 and ERK2 induces Bcl‐xL up‐regulation via inhibition of caspase activities in erythropoietin signaling , 2003, Journal of cellular physiology.

[2]  C. Lacombe,et al.  Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. , 2003, Blood.

[3]  Kenneth Maiese,et al.  Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine Proteases , 2002, Circulation.

[4]  Sung-Liang Yu,et al.  Cyclosporine A regulate oxidative stress‐induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70 , 2002, British journal of pharmacology.

[5]  L. Zon,et al.  Epo-EpoR signaling not required for cardiovascular or neural development , 2002 .

[6]  J. Stamler,et al.  Nitric oxide in the human respiratory cycle , 2002, Nature Medicine.

[7]  H. Rui,et al.  Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. , 2002, Blood.

[8]  B. Habermann,et al.  Apoptosis Protection by the Epo Target Bcl-XL Allows Factor-Independent Differentiation of Primary Erythroblasts , 2002, Current Biology.

[9]  C. Grimm,et al.  HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration , 2002, Nature Medicine.

[10]  J. Stamler,et al.  Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts ... , 2002, Clinical Autonomic Research.

[11]  K. Shyu,et al.  Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. , 2002, Cardiovascular research.

[12]  A. Cerami,et al.  Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jong-Wan Park,et al.  Early Expression of Myocardial HIF-1&agr; in Response to Mechanical Stresses: Regulation by Stretch-Activated Channels and the Phosphatidylinositol 3-Kinase Signaling Pathway , 2002, Circulation research.

[14]  M. Ratajczak,et al.  Biological significance of MAPK, AKT and JAK‐STAT protein activation by various erythropoietic factors in normal human early erythroid cells , 2001, British journal of haematology.

[15]  E. Fleck,et al.  The Apoptotic Regulatory Protein ARC (Apoptosis Repressor with Caspase Recruitment Domain) Prevents Oxidant Stress-mediated Cell Death by Preserving Mitochondrial Function* , 2001, The Journal of Biological Chemistry.

[16]  Stuart A. Lipton,et al.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades , 2001, Nature.

[17]  R. Bolli,et al.  An essential role of the JAK-STAT pathway in ischemic preconditioning , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[19]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Davalli,et al.  Fluorescent dyes for cell viability: an application on prefixed conditions , 2001, Histochemistry and Cell Biology.

[21]  M. Gassmann,et al.  Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. , 2001, Blood.

[22]  R. Johns,et al.  Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. , 2000, Molecular pharmacology.

[23]  M. Gassmann,et al.  Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[26]  R. Lefkowitz,et al.  Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction , 2000 .

[27]  R. Knight,et al.  Ischemia-induced STAT-1 Expression and Activation Play a Critical Role in Cardiomyocyte Apoptosis* , 2000, The Journal of Biological Chemistry.

[28]  M. Hori,et al.  Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  R. Gregory,et al.  Signal transduction in the erythropoietin receptor system. , 1999, Experimental cell research.

[30]  R. Gottlieb,et al.  Apoptosis in Myocardial Ischemia‐Reperfusion , 1999, Annals of the New York Academy of Sciences.

[31]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[32]  N. Chandel,et al.  Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[34]  R. Bolli,et al.  Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. , 1998, Circulation.

[35]  T. Vanden Hoek,et al.  Reactive Oxygen Species Released from Mitochondria during Brief Hypoxia Induce Preconditioning in Cardiomyocytes* , 1998, The Journal of Biological Chemistry.

[36]  J. Ihle.  Cytokine receptor signalling , 1995, Nature.

[37]  J. Downey,et al.  Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. , 1994, The American journal of physiology.

[38]  V. Lim.  Recombinant human erythropoietin in predialysis patients. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  N. Casadevall,et al.  Erythropoietin: physiology and clinical experience. , 1990, Seminars in hematology.

[40]  Polycythaemia due to Hypoxaemia: Advantage or Disadvantage? , 1989, The Lancet.

[41]  M. Weisfeldt,et al.  Direct measurement of free radical generation following reperfusion of ischemic myocardium , 1987 .

[42]  B W Kimes,et al.  Properties of a clonal muscle cell line from rat heart. , 1976, Experimental cell research.

[43]  M. Bernard.  DEFECT OF ORGANIZATION IN THE EXTERNAL EAR. , 1824 .

[44]  W. Jelkmann,et al.  Biology of erythropoietin. , 1994, The Clinical investigator.

[45]  E. Friedman,et al.  Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  J. Caro,et al.  Erythropoietin: from mountain top to bedside. , 1989, Advances in experimental medicine and biology.

[47]  M. Weisfeldt,et al.  Direct measurement of free radical generation following reperfusion of ischemic myocardium. , 1987, Proceedings of the National Academy of Sciences of the United States of America.